|
| Press Releases |
|
 |
|
| Friday, October 21, 2016 |
|
|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. more info >> |
|
| Tuesday, October 4, 2016 |
|
|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. more info >> |
|
| Tuesday, September 20, 2016 |
|
|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI). more info >> |
|
| Wednesday, September 14, 2016 |
|
|
Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has filed for market approval (CE Marking) in Europe for its lead product, a first-in-class radio-enhancer, NBTXR3. more info >> |
|
| Thursday, July 7, 2016 |
|
|
Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx (head and neck cancer, or H&N) in frail and elderly patients. more info >> |
|
| Tuesday, May 31, 2016 |
|
|
Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). more info >> |
|
| Friday, April 29, 2016 |
|
|
Nanobiotix: 2015 Annual Results |
| Nanobiotix (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015. more info >> |
|
| Tuesday, January 5, 2016 |
|
|
Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. more info >> |
|
| Thursday, July 2, 2015 |
|
|
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 |
| Nanobiotix (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more info >> |
|
| Wednesday, June 10, 2015 |
|
|
Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
The USPA and U.S. Polo Assn. Celebrate 135th Anniversary with Global Sport and Fashion Events and Launch of "Born to Play"
Jan 30, 2025 20:00 HKT/SGT
|
|
|
Mazda Production and Sales Results for December 2024 and for January through December 2024
Jan 30, 2025 16:44 JST
|
|
|
Honda、2024年12月度 四輪車 生産・販売・輸出実績を発表
Jan 30, 2025 15:00: JST
|
|
|
トヨタ、2024年 年間（1月－12月）販売・生産・輸出実績を発表
Jan 30, 2025 15:00: JST
|
|
|
Lexus Announces Global Sales Results for 2024
Jan 30, 2025 15:52 JST
|
|
|
三菱重工サーマルシステムズ、2024年度省エネ大賞で「資源エネルギー庁長官賞」を受賞
Jan 30, 2025 14:00: JST
|
|
|
MHI Thermal Systems Receives 2024 Agency for Natural Resources and Energy Commissioner's Award from ECCJ for TEJ35AM Electric-Driven Transport Refrigeration Unit Integrated with Isuzu's ELF EV
Jan 30, 2025 14:13 JST
|
|
|
三菱造船、インドネシア海上保安機構向けの巡視船を受注
Jan 30, 2025 12:00: JST
|
|
|
富士通、スペイン大手の労働災害・疾病相互保険会社ASEPEYO様の保険給付に関わるシステムのモダナイゼーションを支援
Jan 30, 2025 12:00: JST
|
|
|
Mitsubishi Shipbuilding Receives Order for an Offshore Patrol Vessel from the Indonesian Maritime Security Agency
Jan 30, 2025 12:35 JST
|
|
|
Fujitsu and Asepeyo collaborate to modernise the management of occupational benefits and contingencies
Jan 30, 2025 11:56 JST
|
|
|
Fourth Star Launches Immersive Media Streaming Platform
Jan 30, 2025 10:30 HKT/SGT
|
|
|
Suzuki, Daihatsu, and Toyota Decide on the Release Schedule for Mini-Commercial Van Electric Vehicles
Jan 30, 2025 10:56 JST
|
|
|
Supply Chain Specialists OMP Strengthen Leadership to Support Strategic Growth
Jan 30, 2025 09:48 HKT/SGT
|
|
|
A Quantum Leap into Uplisting: Spectral Capital and the Next Generation of Computing
Jan 29, 2025 22:47 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
